Recent reporting, background, and summaries from the health desk.
The Canadian Paediatric Society now recommends universal cholesterol screening for all children aged two to ten, aiming to detect early atherosclerosis and prevent future heart disease. This proactive measure allows for timely interventions, including lifestyle changes, to manage cholesterol levels and significantly reduce the risk of serious cardiovascular issues in adulthood.
Mexican security forces have killed "El Mencho," the notorious leader of the Jalisco New Generation Cartel and one of the world's most wanted drug traffickers, delivering a significant blow to the powerful criminal organization. This high-profile operation in Jalisco has, however, ignited a wave of retaliatory violence across several Mexican states, causing widespread disruption, school cancellations, and urgent travel warnings.
Stanford Medicine researchers have developed a groundbreaking universal nasal spray vaccine designed to offer broad protection against various respiratory threats, including viruses, bacteria, and allergens. This innovative vaccine works by supercharging the lungs' immune defenses, significantly reducing viral levels, preventing severe illness, and blocking allergic reactions in mouse studies.
Major advancements in infectious disease prevention are on the horizon, as Merck unveiled positive Phase 3 trial results for its RSV treatment, clesrovimab, aimed at protecting high-risk young children, and GSK presented new real-world effectiveness data for its Arexvy vaccine. Adding to these developments, the FDA has reversed its decision and will now review Moderna's investigational mRNA-1010 influenza vaccine, signaling a crucial step for its potential approval.
Vanderbilt Health researchers have developed an experimental vaccine that successfully protected animals from *C. difficile* infection, preventing illness, death, and recurrence. This novel vaccine, administered to the colon's mucosal lining, offers a promising new strategy against a leading cause of healthcare-associated infections.
A massive dust storm choked Israel on February 14, 2026, drastically reducing visibility and making Jerusalem and Tel Aviv the world's most polluted cities. Originating from North Africa and the Sahara, the storm prompted health officials to advise vulnerable groups to avoid outdoor activities for safety.
A leading bioethicist firmly states that human head transplants remain an impossible feat, primarily due to the insurmountable challenge of functionally reconnecting the spinal cord. Beyond the technical hurdles, the medical community also grapples with profound ethical dilemmas, dismissing controversial claims while highlighting critical concerns about identity and sensory overload for any potential recipient.
Gaza's healthcare system has catastrophically collapsed, leaving thousands of patients without essential care as critical shortages of medicines and supplies plague the few remaining partially functional hospitals. This dire crisis, fueled by over 930 attacks on health facilities since October 2023, has resulted in 46% of essential medicines and 84% of lab supplies being out of stock, severely limiting life-saving treatments across the Strip.
The World Health Organization has launched a critical appeal for nearly US$1 billion to address 36 global health emergencies in 2026, aiming to provide life-saving care to millions amidst humanitarian crises. Despite declining donor support, this vital funding is emphasized as a strategic investment for global security, especially for acute needs in regions like Gaza, Sudan, and Ukraine.
The World Health Organization issued an urgent warning on January 21, 2026, regarding a newly emerged, highly contagious measles variant that exhibits alarming resistance to existing vaccines. This critical development jeopardizes global measles eradication efforts, prompting immediate WHO-led research into new immunization strategies and a worldwide call for increased vaccination rates.
Mayo Clinic researchers announced on January 19, 2026, a groundbreaking gene therapy that remarkably reversed early-stage Alzheimer's symptoms in human trials. This pivotal development offers unprecedented hope by not only improving cognition but also significantly reducing amyloid plaque buildup, a primary hallmark of the disease.
A U.S. FDA advisory committee has unanimously recommended approval for Eli Lilly's donanemab, an Alzheimer's drug that offers renewed hope by effectively slowing cognitive decline in patients with early-stage disease. This significant 11-0 decision, targeting amyloid plaques, moves the treatment closer to widespread availability and awaits the FDA's final ruling later this year, potentially expanding crucial options for those battling the neurodegenerative condition.